Needle-Sized device could reveal which bladder cancer drug works best

NCT ID NCT06204614

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a tiny implantable device that releases very small amounts of several cancer drugs directly into bladder tumors. The goal is to see if the device is safe and can help doctors figure out which drugs kill the tumor best. Only 18 people with muscle-invasive bladder cancer who are already scheduled for bladder removal surgery will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

implantable microdevice releasing microdoses of methotrexate, carboplatin, avelumab, and paclitaxel

What this could lead to

If successful, this could lead to a way to test multiple cancer drugs directly in a patient's tumor, helping doctors choose the most effective treatment without exposing the whole body to side effects.

What could go wrong

This is a very early, small study with only 18 people, focused on safety and feasibility, not on curing cancer. The device may not work as hoped, and there is a small risk of side effects from the procedure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States